Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | GLS | O94925 | 6/20 | 0.43 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29392091 | 1.00 | GPR139 (0.46) | GPR139PTGS1GLSTRPM8FFAR1 | |
| SCHEMBL17295978 | 1.00 | GPR139 (0.46) | GPR139PTGS1GLSTRPM8FFAR1 | |
| SCHEMBL30337490 | 0.87 | TRPM8 (0.47) | GPR139GLSTRPM8 | |
| SCHEMBL31736098 | 0.86 | GPR139 (0.44) | GPR139PTGS1TRPM8FFAR1PPARG | |
| SCHEMBL18069753 | 0.85 | F9 (0.48) | — | |
| SCHEMBL17295986 | 0.85 | PTGS1 (0.45) | PTGS1GLSPPARG | |
| SCHEMBL17295975 | 0.85 | FFAR1 (0.48) | GPR139GLSTRPM8FFAR1 | |
| SCHEMBL29393863 | 0.85 | FFAR1 (0.48) | GPR139GLSTRPM8FFAR1 | |
| SCHEMBL21326187 | 0.83 | L3MBTL1 (0.56) | PTGS1 | |
| SCHEMBL18890289 | 0.83 | L3MBTL1 (0.56) | PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115594683-B | Glutaminase GLS1 inhibitor and preparation method and application thereof | 杭州禹胜医药科技有限公司 | 2023-06-16 | — | — | CN | disclosed |
| CN-115594683-A | Glutaminase GLS1 inhibitor and preparation method and application thereof | 杭州禹胜医药科技有限公司（CN） | 2023-01-13 | — | — | CN | disclosed |